Investigational agents for autosomal dominant polycystic kidney disease: preclinical and early phase study insights
I Capelli, S Lerario, F Ciurli, GM Berti… - Expert Opinion on …, 2024 - Taylor & Francis
ABSTRACT Introduction Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the
most common inherited kidney condition caused by a single-gene mutation. It leads patients …
most common inherited kidney condition caused by a single-gene mutation. It leads patients …
A Primer for Utilizing Deep Learning and Abdominal MRI Imaging Features to Monitor Autosomal Dominant Polycystic Kidney Disease Progression
Abdominal imaging of autosomal dominant polycystic kidney disease (ADPKD) has
historically focused on detecting complications such as cyst rupture, cyst infection …
historically focused on detecting complications such as cyst rupture, cyst infection …
What is the Appropriate Dose of Tolvaptan in ADPKD?
NK Dahl, VE Torres - Kidney International Reports, 2024 - kireports.org
The half-life of tolvaptan is dose-dependent, with the half-life increasing from 3.3 hours after
a 15 mg dose to 11 hours after a 120 mg dose. 1 Daily split dosing ensures V2 receptor …
a 15 mg dose to 11 hours after a 120 mg dose. 1 Daily split dosing ensures V2 receptor …
Prospective Study on Individualized Dose Adjustment of Tolvaptan Based on Urinary Osmolality in Patients With ADPKD
P Geertsema, D Soonawala, RT Gansevoort… - Kidney International …, 2025 - kireports.org
In their editorial, Dahl et al. 1 write that the study by Roca Oporto et al. 2 offers reassurance
that most patients with autosomal dominant polycystic kidney disease can remain on the …
that most patients with autosomal dominant polycystic kidney disease can remain on the …